Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

This study has been completed.

Sponsored by:	Allergan
Information provided by:	Allergan
ClinicalTrials.gov Identifier:	NCT00300443

Purpose

The purpose of this study is to assess the safety and efficacy of bimatoprost in patients with glaucoma or ocular hypertension

Condition	Intervention	Phase
Ocular Hypertension	Drug: bimatoprost	Phase II Phase III

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma High Blood Pressure

Drug Information available for: Bimatoprost

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Allergan:

Primary Outcome Measures:

Estimated Enrollment:

550

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00300443

Locations

United States, California

Newport Beach, California, United States

Sponsors and Collaborators

Allergan

More Information

Study ID Numbers:	192024-031
Study First Received:	March 7, 2006
Last Updated:	September 25, 2007
ClinicalTrials.gov Identifier:	NCT00300443
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Bimatoprost
Glaucoma
Eye Diseases

Vascular Diseases
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:

Therapeutic Uses
Cardiovascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009